SGMO
Sangamo Therapeutics·NASDAQ
--
--(--)
--
--(--)
SGMO fundamentals
Sangamo Therapeutics (SGMO) released its earnings on Nov 6, 2025: revenue was 581.00K (YoY -98.82%), missed estimates; EPS was -0.11 (YoY -375.00%), missed estimates.
Revenue / YoY
581.00K
-98.82%
EPS / YoY
-0.11
-375.00%
Report date
Nov 6, 2025
SGMO Earnings Call Summary for Q3,2025
- Fabry Disease Breakthrough: ST-920 demonstrates durable kidney and cardiac benefits with 4.5-year follow-up data, FDA reaffirms accelerated approval pathway, and BLA submission planned for Q1 2026.
- Neurology Pipeline Momentum: ST-503 enrollment begins for chronic pain, ST-506 advances toward CTA for prion disease, and STAC-BBB capsid shows promise in preclinical studies.
- Financial Resilience: $6M Pfizer license fee extends cash runway to Q1 2026, with focus on securing a commercialization partner and exploring capital options.
- Patient-Centric Innovation: Gene therapy for Fabry disease and epigenetic regulators for chronic pain address unmet needs, supported by strong preclinical and clinical data.
EPS
Revenue
Revenue & Expenses
SGMO has released its 2025 Q3 earnings report, with revenue of 581.00K, reflecting a YoY change of -98.82%, and net profit of -34.93M, showing a YoY change of -427.31%. The Sankey diagram below clearly presents SGMO's revenue sources and cost distribution.
Key Indicators
Sangamo Therapeutics (SGMO) key financial stats and ratios, covering profitability, financial health, and leverage.
Sangamo Therapeutics (SGMO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Sangamo Therapeutics (SGMO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Sangamo Therapeutics (SGMO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Sangamo Therapeutics (SGMO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Sangamo Therapeutics (SGMO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What guidance did Sangamo Therapeutics's management provide for the next earnings period?What is Sangamo Therapeutics's latest dividend and current dividend yield?What is the market's earnings forecast for Sangamo Therapeutics next quarter?What were the key takeaways from Sangamo Therapeutics’s earnings call?What were the key takeaways from Sangamo Therapeutics's earnings call?What is the revenue and EPS growth rate for Sangamo Therapeutics year over year?What factors drove the changes in Sangamo Therapeutics's revenue and profit?What does Sangamo Therapeutics do and what are its main business segments?
